Aclarion, Inc. (ACON) vs Femasys Inc. (FEMY)
A side-by-side comparison of Aclarion, Inc. and Femasys Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACON
Aclarion, Inc.
$2.30HealthcareDelayed quote: Oct 6, 2026, 2:59 PM EDT
FEMY
Femasys Inc.
$2.06HealthcareDelayed quote: Oct 6, 2026, 2:59 PM EDT
Total return — ACON vs FEMY
growth of $100 · dividends reinvested · last 4yACON -100.0% (-95.1%/yr)FEMY -93.4% (-49.4%/yr)FEMY compounded faster over this window
Log scale — wide-divergence pair
ACON FEMY
ACON vs FEMY: by the numbers
- •ACON is the larger company ($7M vs $6M market cap).
- •Both run net losses; FEMY's is the smaller (-534.27% vs -10978.48% net margin).
- •FEMY grew revenue faster over the past five years (12.97% vs 3.75% CAGR).
Metrics side by side
Valuation
| Metric | ACON | FEMY |
|---|---|---|
| P/S ratio | 78.97 | 2.71 |
| P/B ratio | 0.39 | 1.54 |
Profitability
| Metric | ACON | FEMY |
|---|---|---|
| Gross margin | -291.27% | 61.96% |
| Operating margin | -9312.55% | -763.90% |
| Net margin | -10978.48% | -534.27% |
| ROE | -54.09% | -304.78% |
| ROIC | -57.11% | -209.05% |
Growth (annualized)
| Metric | ACON | FEMY |
|---|---|---|
| Revenue CAGR (5Y) | 3.75% | 12.97% |
| Total return CAGR (5Y) | N/A | -57.27% |
Frequently asked
- Which has grown faster, ACON or FEMY?
- Over the past five years, FEMY grew revenue faster — ACON at a 3.75% CAGR versus FEMY at 12.97%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.